The company

The pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications.

Company

Established in 2003, Diagnoptics is the pioneer and inventor of cutting edge diagnostic devices that can non-invasively diagnose and assess the risk of diabetes and its complications. Its technological advance in detecting fluorescence of Advanced Glycation Endproducts (AGEs) has led to the invention of the AGE Reader – a state of art diagnostic device which can determine the tissue accumulation of AGEs in 12 seconds.

AGEs are essential biomarkers of metabolic and glycemic stress and have been implicated as causative factors in the progression of a host of age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The amount of AGEs in tissue serves as an important risk predictor of diabetes and its complications.

More Information
Request informations

Would you like to learn more about our products? Request any information you wish to receive here.

Contact

Our contact details






Tel:
Fax:
E-mail:


Follow us on LinkedIn

About the company

Find information about Diagnoptics.

Information for patients

Find information about Diagnoptics' products and Advanced Glycation Endproducts.

Information for professionals

Find information about Advanced Glycation Endproducts, the AGE measurement and the clinical validation.a